These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 18258868)

  • 21. Gold in the ivory tower: equity rewards of outlicensing.
    Edwards M; Murray F; Yu R
    Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 23. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

  • 24. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Universities should foster neglected-disease work.
    Chokshi DA
    Nature; 2005 May; 435(7039):143. PubMed ID: 15889064
    [No Abstract]   [Full Text] [Related]  

  • 26. Translational research: moving discovery to practice.
    Zerhouni EA
    Clin Pharmacol Ther; 2007 Jan; 81(1):126-8. PubMed ID: 17186011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The promise of South African biotech.
    Akermann B; Kermani F
    Drug Discov Today; 2006 Nov; 11(21-22):962-5. PubMed ID: 17055404
    [No Abstract]   [Full Text] [Related]  

  • 28. Deal watch: Trends in platform technology deal-making.
    Walker J; Jacob J
    Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395
    [No Abstract]   [Full Text] [Related]  

  • 29. Orphan drugs of the future?
    Service RF
    Science; 2004 Mar; 303(5665):1798. PubMed ID: 15031491
    [No Abstract]   [Full Text] [Related]  

  • 30. A new prize system for drug innovation.
    Gandjour A; Chernyak N
    Health Policy; 2011 Oct; 102(2-3):170-7. PubMed ID: 21724290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mega-prizes in medicine: big cash awards may stimulate useful and rapid therapeutic innovation.
    Charlton BG
    Med Hypotheses; 2007; 68(1):1-3. PubMed ID: 17052861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. US, Brazil tangle over IP rights to drugs.
    Fox JL
    Nat Biotechnol; 2001 Aug; 19(8):698. PubMed ID: 11479544
    [No Abstract]   [Full Text] [Related]  

  • 33. The market for follow-on biologics: how will it evolve?
    Grabowski H; Cockburn I; Long G
    Health Aff (Millwood); 2006; 25(5):1291-301. PubMed ID: 16966725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pfizer slashes R&D.
    Cressey D
    Nature; 2011 Feb; 470(7333):154. PubMed ID: 21307908
    [No Abstract]   [Full Text] [Related]  

  • 35. In search of a compromised solution to the problem arising from patenting biomedical research tools.
    Derzko NM
    Santa Clara Comput High Technol Law J; 2004; 20(2):347-410. PubMed ID: 16493840
    [No Abstract]   [Full Text] [Related]  

  • 36. The Hyper-Commons: how open science prizes can expand and level the medical research playing field.
    Hynek P
    Rejuvenation Res; 2008 Dec; 11(6):1065-72. PubMed ID: 19119862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 38. Don't feed the trolls.
    Nature; 2014 Jun; 510(7503):7. PubMed ID: 24910865
    [No Abstract]   [Full Text] [Related]  

  • 39. Among the best.
    Jayaraman KS
    Nature; 2005 Jul; 436(7050):492-5. PubMed ID: 16049476
    [No Abstract]   [Full Text] [Related]  

  • 40. Premier funds biotechnology.
    Scott L
    Mod Healthc; 1996 Apr; 26(18):50. PubMed ID: 10157168
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.